HanAll to distribute AB-Life in South Korea

Related tags Cholesterol United states

AB-Biotics has signed an agreement with HanAll BioPharma to distribute its cholesterol-lowering probiotic in Korea. The deal will give the Korean company a 10-year licence to exclusively distribute the AB-Life probiotic across the country. 

The Spanish company claims its product will reduce total cholesterol levels by between 14% and 18%. AB-Life will be released in the next six months on the Korean market, where the prevalence of hypercholesterolemia is estimated to be 8.9% in men and 10.4% in women, according to a study by the Korea Medical Insurance Corporation.

"Korea opens the Asian door for our international expansion. Thanks to HanAll BioPharma, we can enter with a local and very well positioned partnership”, said Miquel Angel Bonachera, co-founder and CEO of AB-Biotics.

HanAll has had nearly 40 years in the market and is listed on the Korean Stock Exchange. The company had a turnover over US$100 million dollars in 2010. 

The deal with HanAll is the fifth international licence agreement signed by AB-Biotics so far this year. AB-Life already has agreements in Mexico, Venezuela and Brazil, while Aceto Corporation will distribute it in the United States and Canada.

Related products

show more

Related suppliers

Follow us


View more